Compare · RVTY vs TBIO
RVTY vs TBIO
Side-by-side comparison of Revvity Inc. (RVTY) and Telesis Bio Inc. (TBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RVTY and TBIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.62B, about 4.1x TBIO ($2.82B).
- Over the past year, RVTY is up 8.2% and TBIO is up 0.0% - RVTY leads by 8.2 points.
- RVTY has hit the wire 2 times in the past 4 weeks while TBIO has been quiet.
- RVTY has more recent analyst coverage (19 ratings vs 4 for TBIO).
- Company
- Revvity Inc.
- Telesis Bio Inc.
- Price
- $104.15+3.81%
- $3.14-18.86%
- Market cap
- $11.62B
- $2.82B
- 1M return
- +3.10%
- +0.00%
- 1Y return
- +8.19%
- +0.00%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 0
- Recent ratings
- 19
- 4
Telesis Bio Inc.
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)
Latest TBIO
- Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
- Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis
- SEC Form 15-12G filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form EFFECT filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form POS AM filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.
- SEC Form S-8 POS filed by Telesis Bio Inc.